Nura Bio
4 known investors
Find your way into Nura Bio
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
Investors · 4
The Column Group✓ verifiedSan Francisco · $30M
Samsara BioCapitalPalo Alto
Sanofi VenturesCambridge · $5M
Also in the syndicate · 1
Euclidean Capital
Funding
SEC filings, press & company announcements$73.8M disclosed across 1 of 3 rounds · 2024–2026
- $73.8MSeries BJun 2026 · 3 sources
The Column Group (lead), Euclidean Capital, Samsara BioCapital, Sanofi Ventures
Source ↗ - Undisclosed amountSeries ASep 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Nura Bio do?
- Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
- Who are Nura Bio's investors?
- Nura Bio's investors include The Column Group, Samsara BioCapital, Sanofi Ventures.
- How much funding has Nura Bio raised?
- Nura Bio has disclosed $73.8M raised across 1 of its 3 known rounds.